tradingkey.logo

Genfit SA

GNFT
4.850USD
0.000
收盘 12/26, 16:00美东报价延迟15分钟
242.51M总市值
--市盈率 TTM

Genfit SA

4.850
0.000

关于 Genfit SA 公司

Genfit SA is a France-based biopharmaceutical company focused on the discovery and development of therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, particularly due to a lack of approved treatments. The Company provides therapeutic and diagnostic solutions for rare and serious liver diseases , with a particular interest in diseases with largely unmet medical needs. Its laboratory capabilities include pharmacology, molecular and cellular biology, drug candidate screening, medicinal and analytical chemistry, biochemistry, omics analyses, and data science. Its in-house biobank allows to have unparalleled control and precision in the handling and preservation of biological samples, which is crucial to research. The Company leverage artificial intelligence (image processing tools and language models) to create tools that accelerate daily work and decision-making.

Genfit SA简介

公司代码GNFT
公司名称Genfit SA
上市日期Dec 19, 2006
CEOPrigent (Pascal)
员工数量180
证券类型Depository Receipt
年结日Dec 19
公司地址Parc Eurasante 885 avenue Eugene Avinee
城市LOOS
上市交易所NASDAQ OMX - NASDAQ BASIC
国家France
邮编59120
电话33320164000
网址https://www.genfit.fr/
公司代码GNFT
上市日期Dec 19, 2006
CEOPrigent (Pascal)

Genfit SA公司高管

名称
名称/职务
职务
持股
持股变动
Mr. Tom Huijbers
Mr. Tom Huijbers
Executive Vice President - Regulatory
Executive Vice President - Regulatory
--
--
Ms. Sandra Silvestri, M.D., Ph.D.
Ms. Sandra Silvestri, M.D., Ph.D.
Director, Representative of IPSEN
Director, Representative of IPSEN
--
--
Ms. Florence Sejourne
Ms. Florence Sejourne
Director, Representative of Biotech Avenir SAS
Director, Representative of Biotech Avenir SAS
--
--
Ms. Katherine Bach Kalin
Ms. Katherine Bach Kalin
Independent Director
Independent Director
--
--
Mr. Pascal Caisey
Mr. Pascal Caisey
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Pascal Prigent
Mr. Pascal Prigent
Chief Executive Officer
Chief Executive Officer
--
--
Mr. John Brozek
Mr. John Brozek
Executive Vice President - Data and Information Technology
Executive Vice President - Data and Information Technology
--
--
Mr. Jean-Christophe Marcoux
Mr. Jean-Christophe Marcoux
Chief Corporate Affairs Officer, Head of Investor Relations, Head of ESG
Chief Corporate Affairs Officer, Head of Investor Relations, Head of ESG
--
--
Dr. Catherine Larue, Ph.D.
Dr. Catherine Larue, Ph.D.
Independent Director
Independent Director
--
--
Dr. Dean W. Hum, Ph.D.
Dr. Dean W. Hum, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Tom Huijbers
Mr. Tom Huijbers
Executive Vice President - Regulatory
Executive Vice President - Regulatory
--
--
Ms. Sandra Silvestri, M.D., Ph.D.
Ms. Sandra Silvestri, M.D., Ph.D.
Director, Representative of IPSEN
Director, Representative of IPSEN
--
--
Ms. Florence Sejourne
Ms. Florence Sejourne
Director, Representative of Biotech Avenir SAS
Director, Representative of Biotech Avenir SAS
--
--
Ms. Katherine Bach Kalin
Ms. Katherine Bach Kalin
Independent Director
Independent Director
--
--
Mr. Pascal Caisey
Mr. Pascal Caisey
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Pascal Prigent
Mr. Pascal Prigent
Chief Executive Officer
Chief Executive Officer
--
--

收入明细

由于公司未披露,未能获取相关数据
由于公司未披露,未能获取相关数据
业务
地区
由于公司未披露,未能获取相关数据

股东统计

更新时间: 11月17日 周一
更新时间: 11月17日 周一
持股股东
股东类型
持股股东
持股股东
占比
AllianceBernstein L.P.
0.04%
Morgan Stanley & Co. International Plc
0.04%
Summit Financial, LLC
0.04%
UBS Financial Services, Inc.
0.01%
其他
99.87%
持股股东
持股股东
占比
AllianceBernstein L.P.
0.04%
Morgan Stanley & Co. International Plc
0.04%
Summit Financial, LLC
0.04%
UBS Financial Services, Inc.
0.01%
其他
99.87%
股东类型
持股股东
占比
Investment Advisor/Hedge Fund
0.05%
Investment Advisor
0.05%
Research Firm
0.04%
其他
99.86%

机构持股

更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
20
80.73K
0.16%
-686.95K
2025Q2
22
234.11K
0.47%
-547.30K
2025Q1
25
259.00K
0.52%
-1.29M
2024Q4
26
260.49K
0.52%
-1.21M
2024Q3
28
127.35K
0.26%
-1.36M
2024Q2
31
97.15K
0.20%
-1.36M
2024Q1
31
97.93K
0.20%
-1.42M
2023Q4
31
648.17K
1.30%
-1.34M
2023Q3
32
1.16M
2.33%
-1.43M
2023Q2
30
1.77M
3.54%
-496.41K
查看更多

股东持股明细

名称
持股数
占比
持股变动
变动比例
公告日期
AllianceBernstein L.P.
22.36K
0.04%
+13.38K
+148.94%
Jun 30, 2024
Morgan Stanley & Co. International Plc
27.42K
0.05%
+1.90K
+7.45%
Jun 30, 2025
UBS Financial Services, Inc.
4.08K
0.01%
+963.00
+30.89%
Jun 30, 2025
Geode Capital Management, L.L.C.
3.21K
0.01%
--
--
Aug 31, 2025
Osaic Holdings, Inc.
225.00
0%
+225.00
--
Jun 30, 2025
Principal Securities Inc
24.00
0%
+24.00
--
Jun 30, 2025
Qube Research & Technologies Ltd
--
0%
-98.00
-100.00%
Sep 30, 2024
BofA Global Research (US)
1.00
0%
-16.00
-94.12%
Jun 30, 2025
Millennium Management LLC
--
0%
-131.48K
-100.00%
Jun 30, 2025
查看更多

持股ETF

更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
ActivePassive International Equity ETF
0%
ActivePassive International Equity ETF
占比0%

分红派息

近5年累计派现 0.00 美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据

拆合股

公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据

常见问题

Genfit SA的前五大股东是谁?

Genfit SA 的前五大股东如下:
AllianceBernstein L.P.持有股份:22.36K,占总股份比例:0.04%。
Morgan Stanley & Co. International Plc持有股份:27.42K,占总股份比例:0.05%。
UBS Financial Services, Inc.持有股份:4.08K,占总股份比例:0.01%。
Geode Capital Management, L.L.C.持有股份:3.21K,占总股份比例:0.01%。
Osaic Holdings, Inc.持有股份:225.00,占总股份比例:0.00%。

Genfit SA的前三大股东类型是什么?

Genfit SA 的前三大股东类型分别是:
AllianceBernstein L.P.
Morgan Stanley & Co. International Plc
Summit Financial, LLC

有多少机构持有Genfit SA(GNFT)的股份?

截至2025Q3,共有20家机构持有Genfit SA的股份,合计持有的股份价值约为80.73K,占公司总股份的0.16%。与2025Q2相比,机构持股有所增加,增幅为-0.31%。

哪个业务部门对Genfit SA的收入贡献最大?

在--,--业务部门对Genfit SA的收入贡献最大,创收--,占总收入的--%。
KeyAI